During the last session, Akero Therapeutics Inc (NASDAQ:AKRO)’s traded shares were 0.52 million, with the beta value of the company hitting -0.04. At the end of the trading day, the stock’s price was $37.63, reflecting an intraday gain of 0.51% or $0.19. The 52-week high for the AKRO share is $58.40, that puts it down -55.2 from that peak though still a striking 52.54% gain since the share price plummeted to a 52-week low of $17.86. The company’s market capitalization is $3.00B, and the average intraday trading volume over the past 10 days was 1.32 million shares, and the average trade volume was 1.43 million shares over the past three months.
Akero Therapeutics Inc (AKRO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. AKRO has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.99.
Akero Therapeutics Inc (NASDAQ:AKRO) trade information
Akero Therapeutics Inc (AKRO) registered a 0.51% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 0.51% in intraday trading to $37.63, hitting a weekly high. The stock’s 5-day price performance is 8.07%, and it has moved by -15.97% in 30 days. Based on these gigs, the overall price performance for the year is 72.69%. The short interest in Akero Therapeutics Inc (NASDAQ:AKRO) is 5.49 million shares and it means that shorts have 5.71 day(s) to cover.
The consensus price target of analysts on Wall Street is $45, which implies an increase of 16.38% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $38 and $56 respectively. As a result, AKRO is trading at a discount of -48.82% off the target high and -0.98% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -5.28%. While earnings are projected to return -14.49% in 2025, the next five years will return -8.19% per annum.
AKRO Dividends
Akero Therapeutics Inc is due to release its next quarterly earnings on 2025-Feb-27. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Akero Therapeutics Inc (NASDAQ:AKRO)’s Major holders
Akero Therapeutics Inc insiders own 2.30% of total outstanding shares while institutional holders control 94.19%, with the float percentage being 96.41%. JANUS HENDERSON GROUP PLC is the largest shareholder of the company, while 271.0 institutions own stock in it. As of 2024-06-30, the company held over 6.88 million shares (or 9.9425% of all shares), a total value of $161.28 million in shares.
The next largest institutional holding, with 5.59 million shares, is of BLACKROCK INC.’s that is approximately 8.0778% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $131.06 million.
Also, the Mutual Funds coming in first place with the largest holdings of Akero Therapeutics Inc (AKRO) shares are VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and iShares Trust-iShares Russell 2000 ETF. Data provided on Jan 31, 2025 indicates that VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund owns about 4.07 shares. This amounts to just over 5.11 percent of the company’s overall shares, with a $153.15 million market value. The same data shows that the other fund manager holds slightly less at 1.96, or about 2.46% of the stock, which is worth about $73.84 million.
